Skip to main content
NCBI home page
Gut logoLink to Gut
. 2002 May;50(Suppl 3):iii47–iii53. doi: 10.1136/gut.50.suppl_3.iii47

Small therapeutic molecules for the treatment of inflammatory bowel disease

S J H van Deventer
PMCID: PMC1867685  PMID: 11953333

Full Text

The Full Text of this article is available as a PDF (102.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong A. M., Foulkes R., Jennings G., Gannon C., Kirk S. J., Gardiner K. R. Tumour necrosis factor inhibitors reduce the acute-phase response in hapten-induced colitis. Br J Surg. 2001 Feb;88(2):235–240. doi: 10.1046/j.1365-2168.2001.01646.x. [DOI] [PubMed] [Google Scholar]
  2. Auwerda J. J., Zijlstra F. J., Tak C. J., van den Ingh H. F., Wilson J. H., Ouwendijk R. J. Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol. 2001 Apr;13(4):397–400. doi: 10.1097/00042737-200104000-00016. [DOI] [PubMed] [Google Scholar]
  3. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia. 1999 Sep;42(9):1033–1049. doi: 10.1007/s001250051268. [DOI] [PubMed] [Google Scholar]
  4. Badger A. M., Bradbeer J. N., Votta B., Lee J. C., Adams J. L., Griswold D. E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996 Dec;279(3):1453–1461. [PubMed] [Google Scholar]
  5. Badger A. M., Griswold D. E., Kapadia R., Blake S., Swift B. A., Hoffman S. J., Stroup G. B., Webb E., Rieman D. J., Gowen M. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 2000 Jan;43(1):175–183. doi: 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  6. Baeuerle P. A. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell. 1998 Dec 11;95(6):729–731. doi: 10.1016/s0092-8674(00)81694-3. [DOI] [PubMed] [Google Scholar]
  7. Bar-Tana J. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans. Toxicol Lett. 2001 Mar 31;120(1-3):9–19. doi: 10.1016/s0378-4274(01)00302-2. [DOI] [PubMed] [Google Scholar]
  8. Barnette M. S., Christensen S. B., Essayan D. M., Grous M., Prabhakar U., Rush J. A., Kagey-Sobotka A., Torphy T. J. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther. 1998 Jan;284(1):420–426. [PubMed] [Google Scholar]
  9. Bauditz J., Haemling J., Ortner M., Lochs H., Raedler A., Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut. 1997 Apr;40(4):470–474. doi: 10.1136/gut.40.4.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Becker C., Barbulescu K., Wirtz S., Meyer zum Büschenfelde K. H., Pettersson S., Neurath M. F. Constitutive and inducible in vivo protein-DNA interactions at the tumor necrosis factor-alpha promoter in primary human T lymphocytes. Gene Expr. 1999;8(2):115–127. [PMC free article] [PubMed] [Google Scholar]
  11. Bekker L. G., Haslett P., Maartens G., Steyn L., Kaplan G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis. 2000 Mar;181(3):954–965. doi: 10.1086/315328. [DOI] [PubMed] [Google Scholar]
  12. Bemelman W. A., Slors J. F., Dunker M. S., van Hogezand R. A., van Deventer S. J., Ringers J., Griffioen G., Gouma D. J. Laparoscopic-assisted vs. open ileocolic resection for Crohn's disease. A comparative study. Surg Endosc. 2000 Aug;14(8):721–725. doi: 10.1007/s004640000186. [DOI] [PubMed] [Google Scholar]
  13. Bertrán X., Mañ J., Fernández-Bañares F., Castellá E., Bartolí R., Ojanguren I., Esteve M., Gassull M. A. Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis. Gut. 1996 Jun;38(6):899–904. doi: 10.1136/gut.38.6.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Blanchard H. S., Dernis-Labous E., Lamarque D., Nhieu J. T., Szepes Z., Fléjou J. F., Wollman E., Whittle B. J., Breban M. Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human beta2 microglobulin transgenic rats. Eur Cytokine Netw. 2001 Mar;12(1):111–118. [PubMed] [Google Scholar]
  15. Brown P. D. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs. 2000 Sep;9(9):2167–2177. doi: 10.1517/13543784.9.9.2167. [DOI] [PubMed] [Google Scholar]
  16. Calabrese L., Fleischer A. B. Thalidomide: current and potential clinical applications. Am J Med. 2000 Apr 15;108(6):487–495. doi: 10.1016/s0002-9343(99)00408-8. [DOI] [PubMed] [Google Scholar]
  17. Carty E., Macey M., McCartney S. A., Rampton D. S. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000 Jun;14(6):807–817. doi: 10.1046/j.1365-2036.2000.00779.x. [DOI] [PubMed] [Google Scholar]
  18. Casellas F., Papo M., Guarner F., Antolín M., Segura R. M., Armengol J. R., Malagelada J. R. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol. 1995 Mar;7(3):221–226. [PubMed] [Google Scholar]
  19. Cha B. S., Ciaraldi T. P., Carter L., Nikoulina S. E., Mudaliar S., Mukherjee R., Paterniti J. R., Jr, Henry R. R. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia. 2001 Apr;44(4):444–452. doi: 10.1007/s001250051642. [DOI] [PubMed] [Google Scholar]
  20. Chao N. J., Parker P. M., Niland J. C., Wong R. M., Dagis A., Long G. D., Nademanee A. P., Negrin R. S., Snyder D. S., Hu W. W. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant. 1996 May;2(2):86–92. [PubMed] [Google Scholar]
  21. Chinetti G., Fruchart J. C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000 Oct;49(10):497–505. doi: 10.1007/s000110050622. [DOI] [PubMed] [Google Scholar]
  22. Chinetti G., Griglio S., Antonucci M., Torra I. P., Delerive P., Majd Z., Fruchart J. C., Chapman J., Najib J., Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998 Oct 2;273(40):25573–25580. doi: 10.1074/jbc.273.40.25573. [DOI] [PubMed] [Google Scholar]
  23. Corral L. G., Haslett P. A., Muller G. W., Chen R., Wong L. M., Ocampo C. J., Patterson R. T., Stirling D. I., Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999 Jul 1;163(1):380–386. [PubMed] [Google Scholar]
  24. Davis R. J. Signal transduction by the JNK group of MAP kinases. Cell. 2000 Oct 13;103(2):239–252. doi: 10.1016/s0092-8674(00)00116-1. [DOI] [PubMed] [Google Scholar]
  25. Dekkers P. E., Lauw F. N., ten Hove T., te Velde A. A., Lumley P., Becherer D., van Deventer S. J., van der Poll T. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. Blood. 1999 Oct 1;94(7):2252–2258. [PubMed] [Google Scholar]
  26. Dekkers P. E., ten Hove T., Lauw F. N., Koene H. R., Lumley P., van Deventer S. J., van der Poll T. The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans. Infect Immun. 2000 May;68(5):3036–3039. doi: 10.1128/iai.68.5.3036-3039.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med. 2001 Apr 2;193(7):827–838. doi: 10.1084/jem.193.7.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Diaz-Granados N., Howe K., Lu J., McKay D. M. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol. 2000 Jun;156(6):2169–2177. doi: 10.1016/S0002-9440(10)65087-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Dikopoulos N., Nüssler A. K., Liptay S., Bachem M., Reinshagen M., Stiegler M., Schmid R. M., Adler G., Weidenbach H. Inhibition of nitric oxide synthesis by aminoguanidine increases intestinal damage in the acute phase of rat TNB-colitis. Eur J Clin Invest. 2001 Mar;31(3):234–239. doi: 10.1046/j.1365-2362.2001.00802.x. [DOI] [PubMed] [Google Scholar]
  30. DuBois R. N., Gupta R., Brockman J., Reddy B. S., Krakow S. L., Lazar M. A. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis. 1998 Jan;19(1):49–53. doi: 10.1093/carcin/19.1.49. [DOI] [PubMed] [Google Scholar]
  31. Ehrenpreis E. D., Kane S. V., Cohen L. B., Cohen R. D., Hanauer S. B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec;117(6):1271–1277. doi: 10.1016/s0016-5085(99)70276-3. [DOI] [PubMed] [Google Scholar]
  32. Elewaut D., DiDonato J. A., Kim J. M., Truong F., Eckmann L., Kagnoff M. F. NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol. 1999 Aug 1;163(3):1457–1466. [PubMed] [Google Scholar]
  33. Eliakim R., Karmeli F., Razin E., Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology. 1988 Nov;95(5):1167–1172. doi: 10.1016/0016-5085(88)90346-0. [DOI] [PubMed] [Google Scholar]
  34. Evans J. M., McMahon A. D., Murray F. E., McDevitt D. G., MacDonald T. M. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997 May;40(5):619–622. doi: 10.1136/gut.40.5.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Facchini S., Candusso M., Martelossi S., Liubich M., Panfili E., Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr. 2001 Feb;32(2):178–181. doi: 10.1097/00005176-200102000-00016. [DOI] [PubMed] [Google Scholar]
  36. Faveeuw C., Fougeray S., Angeli V., Fontaine J., Chinetti G., Gosset P., Delerive P., Maliszewski C., Capron M., Staels B. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. 2000 Dec 15;486(3):261–266. doi: 10.1016/s0014-5793(00)02319-x. [DOI] [PubMed] [Google Scholar]
  37. Felder J. B., Korelitz B. I., Rajapakse R., Schwarz S., Horatagis A. P., Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000 Aug;95(8):1949–1954. doi: 10.1111/j.1572-0241.2000.02262.x. [DOI] [PubMed] [Google Scholar]
  38. Fujiwara T., Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci. 2000 Oct 6;67(20):2405–2416. doi: 10.1016/s0024-3205(00)00829-8. [DOI] [PubMed] [Google Scholar]
  39. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J. M., Crimmin M., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol. 1995 May;57(5):774–777. doi: 10.1002/jlb.57.5.774. [DOI] [PubMed] [Google Scholar]
  40. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994 Aug 18;370(6490):555–557. doi: 10.1038/370555a0. [DOI] [PubMed] [Google Scholar]
  41. Ghosh S., May M. J., Kopp E. B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–260. doi: 10.1146/annurev.immunol.16.1.225. [DOI] [PubMed] [Google Scholar]
  42. Godkin A. J., De Belder A. J., Villa L., Wong A., Beesley J. E., Kane S. P., Martin J. F. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest. 1996 Oct;26(10):867–872. doi: 10.1111/j.1365-2362.1996.tb02131.x. [DOI] [PubMed] [Google Scholar]
  43. Gori A., Rossi M. C., Trabattoni D., Marchetti G., Fusi M. L., Molteni C., Clerici M., Franzetti1 F. Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection. J Infect Dis. 2000 Aug;182(2):639–640. doi: 10.1086/315721. [DOI] [PubMed] [Google Scholar]
  44. Griswold D. E., Webb E. F., Badger A. M., Gorycki P. D., Levandoski P. A., Barnette M. A., Grous M., Christensen S., Torphy T. J. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther. 1998 Nov;287(2):705–711. [PubMed] [Google Scholar]
  45. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001 Feb;13(2):85–94. doi: 10.1016/s0898-6568(00)00149-2. [DOI] [PubMed] [Google Scholar]
  46. Hammerschmidt D. E., Kotasek D., McCarthy T., Huh P. W., Freyburger G., Vercellotti G. M. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med. 1988 Aug;112(2):254–263. [PubMed] [Google Scholar]
  47. Hamuryudan V., Mat C., Saip S., Ozyazgan Y., Siva A., Yurdakul S., Zwingenberger K., Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998 Mar 15;128(6):443–450. doi: 10.7326/0003-4819-128-6-199803150-00004. [DOI] [PubMed] [Google Scholar]
  48. Han J., Huez G., Beutler B. Interactive effects of the tumor necrosis factor promoter and 3'-untranslated regions. J Immunol. 1991 Mar 15;146(6):1843–1848. [PubMed] [Google Scholar]
  49. Han J., Lee J. D., Bibbs L., Ulevitch R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994 Aug 5;265(5173):808–811. doi: 10.1126/science.7914033. [DOI] [PubMed] [Google Scholar]
  50. Han J., Richter B., Li Z., Kravchenko V., Ulevitch R. J. Molecular cloning of human p38 MAP kinase. Biochim Biophys Acta. 1995 Mar 16;1265(2-3):224–227. doi: 10.1016/0167-4889(95)00002-a. [DOI] [PubMed] [Google Scholar]
  51. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990 Jul 1;172(1):391–394. doi: 10.1084/jem.172.1.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Hansen H. P., Dietrich S., Kisseleva T., Mokros T., Mentlein R., Lange H. H., Murphy G., Lemke H. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol. 2000 Dec 15;165(12):6703–6709. doi: 10.4049/jimmunol.165.12.6703. [DOI] [PubMed] [Google Scholar]
  53. Hartmann G., Bidlingmaier C., Siegmund B., Albrich S., Schulze J., Tschoep K., Eigler A., Lehr H. A., Endres S. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther. 2000 Jan;292(1):22–30. [PubMed] [Google Scholar]
  54. Haslett P. A., Corral L. G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998 Jun 1;187(11):1885–1892. doi: 10.1084/jem.187.11.1885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Haslett P., Hempstead M., Seidman C., Diakun J., Vasquez D., Freedman V. H., Kaplan G. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):1047–1054. doi: 10.1089/aid.1997.13.1047. [DOI] [PubMed] [Google Scholar]
  56. Hawkey C. J., Dube L. M., Rountree L. V., Linnen P. J., Lancaster J. F. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology. 1997 Mar;112(3):718–724. doi: 10.1053/gast.1997.v112.pm9041232. [DOI] [PubMed] [Google Scholar]
  57. Heuschkel R. B., MacDonald T. T., Monteleone G., Bajaj-Elliott M., Smith J. A., Pender S. L. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut. 2000 Jul;47(1):57–62. doi: 10.1136/gut.47.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Hidi R., Timmermans S., Liu E., Schudt C., Dent G., Holgate S. T., Djukanović R. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J. 2000 Feb;15(2):342–349. doi: 10.1034/j.1399-3003.2000.15b21.x. [DOI] [PubMed] [Google Scholar]
  59. Hoet B., Arnout J., Deckmyn H., Vermylen J. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor. Thromb Haemost. 1993 Nov 15;70(5):822–825. [PubMed] [Google Scholar]
  60. Hogaboam C. M., Jacobson K., Collins S. M., Blennerhassett M. G. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol. 1995 Apr;268(4 Pt 1):G673–G684. doi: 10.1152/ajpgi.1995.268.4.G673. [DOI] [PubMed] [Google Scholar]
  61. Huizinga T. W., Dijkmans B. A., van der Velde E. A., van de Pouw Kraan T. C., Verweij C. L., Breedveld F. C. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1996 Nov;55(11):833–836. doi: 10.1136/ard.55.11.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Ikeda I., Kasajima T., Ishiyama S., Shimojo T., Takeo Y., Nishikawa T., Kameoka S., Hiroe M., Mitsunaga A. Distribution of inducible nitric oxide synthase in ulcerative colitis. Am J Gastroenterol. 1997 Aug;92(8):1339–1341. [PubMed] [Google Scholar]
  63. Iwashita E., Miyahara T., Hino K., Tokunaga T., Wakisaka H., Sawazaki Y. High nitric oxide synthase activity in endothelial cells in ulcerative colitis. J Gastroenterol. 1995 Aug;30(4):551–554. doi: 10.1007/BF02347578. [DOI] [PubMed] [Google Scholar]
  64. Jain S., Pulikuri S., Zhu Y., Qi C., Kanwar Y. S., Yeldandi A. V., Rao M. S., Reddy J. K. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol. 1998 Aug;153(2):349–354. doi: 10.1016/s0002-9440(10)65577-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Janssen-Heininger Y. M., Poynter M. E., Baeuerle P. A. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med. 2000 May 1;28(9):1317–1327. doi: 10.1016/s0891-5849(00)00218-5. [DOI] [PubMed] [Google Scholar]
  66. Jobin C., Bradham C. A., Russo M. P., Juma B., Narula A. S., Brenner D. A., Sartor R. B. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999 Sep 15;163(6):3474–3483. [PubMed] [Google Scholar]
  67. Jobin C., Hellerbrand C., Licato L. L., Brenner D. A., Sartor R. B. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut. 1998 Jun;42(6):779–787. doi: 10.1136/gut.42.6.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Kanauchi O., Andoh A., Iwanaga T., Fujiyama Y., Mitsuyama K., Toyonaga A., Bamba T. Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model. J Gastroenterol Hepatol. 1999 Dec;14(12):1173–1179. doi: 10.1046/j.1440-1746.1999.02025.x. [DOI] [PubMed] [Google Scholar]
  69. Kaplan G., Thomas S., Fierer D. S., Mulligan K., Haslett P. A., Fessel W. J., Smith L. G., Kook K. A., Stirling D., Schambelan M. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1345–1355. doi: 10.1089/08892220050140892. [DOI] [PubMed] [Google Scholar]
  70. Kasyapa C. S., Stentz C. L., Davey M. P., Carr D. W. Regulation of IL-15-stimulated TNF-alpha production by rolipram. J Immunol. 1999 Sep 1;163(5):2836–2843. [PubMed] [Google Scholar]
  71. Keesal N., Wasserman M. J., Bookman A., Lapp V., Weber D. A., Keystone E. C. Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol. 1999 Nov;26(11):2344–2347. [PubMed] [Google Scholar]
  72. Kiss J., Lamarque D., Delchier J. C., Whittle B. J. Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol. 1997 Oct 8;336(2-3):219–224. doi: 10.1016/s0014-2999(97)01246-6. [DOI] [PubMed] [Google Scholar]
  73. Krakauer T. Pentoxifylline inhibits ICAM-1 expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells. Immunopharmacology. 2000 Mar;46(3):253–261. doi: 10.1016/s0162-3109(99)00186-1. [DOI] [PubMed] [Google Scholar]
  74. Kuipers B., van der Poll T., Levi M., van Deventer S. J., ten Cate H., Imai Y., Hack C. E., ten Cate J. W. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. J Immunol. 1994 Mar 1;152(5):2438–2446. [PubMed] [Google Scholar]
  75. Larsson H. Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). J Intern Med. 1990 Oct;228(4):405–407. doi: 10.1111/j.1365-2796.1990.tb00253.x. [DOI] [PubMed] [Google Scholar]
  76. Lawrence J. M., Reckless J. P. Pioglitazone. Int J Clin Pract. 2000 Nov;54(9):614–618. [PubMed] [Google Scholar]
  77. Lee J. C., Laydon J. T., McDonnell P. C., Gallagher T. F., Kumar S., Green D., McNulty D., Blumenthal M. J., Heys J. R., Landvatter S. W. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994 Dec 22;372(6508):739–746. doi: 10.1038/372739a0. [DOI] [PubMed] [Google Scholar]
  78. Leonard N., Bishop A. E., Polak J. M., Talbot I. C. Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment. J Clin Pathol. 1998 Oct;51(10):750–753. doi: 10.1136/jcp.51.10.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Levi M., ten Cate H., Bauer K. A., van der Poll T., Edgington T. S., Büller H. R., van Deventer S. J., Hack C. E., ten Cate J. W., Rosenberg R. D. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994 Jan;93(1):114–120. doi: 10.1172/JCI116934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Longo W. E., Polities G., Vernava A. M., 3rd, Deshpande Y., Niehoff M., Chandel B., Kulkarni A., Kaminski D. L. Platelet-activating factor mediates trinitrobenzene induced colitis. Prostaglandins Leukot Essent Fatty Acids. 1994 Dec;51(6):419–424. doi: 10.1016/0952-3278(94)90059-0. [DOI] [PubMed] [Google Scholar]
  81. Lundberg J. O., Hellström P. M., Lundberg J. M., Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet. 1994 Dec 17;344(8938):1673–1674. doi: 10.1016/s0140-6736(94)90460-x. [DOI] [PubMed] [Google Scholar]
  82. Marriott J. B., Westby M., Cookson S., Guckian M., Goodbourn S., Muller G., Shire M. G., Stirling D., Dalgleish A. G. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol. 1998 Oct 15;161(8):4236–4243. [PubMed] [Google Scholar]
  83. McGeehan G. M., Becherer J. D., Bast R. C., Jr, Boyer C. M., Champion B., Connolly K. M., Conway J. G., Furdon P., Karp S., Kidao S. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994 Aug 18;370(6490):558–561. doi: 10.1038/370558a0. [DOI] [PubMed] [Google Scholar]
  84. Meenan J., Grool T. A., Hommes D. W., Dijkhuizen S., ten Kate F. J., Wood M., Whittaker M., Tytgat G. N., van Deventer S. J. Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis. Eur J Gastroenterol Hepatol. 1996 Jun;8(6):569–573. doi: 10.1097/00042737-199606000-00014. [DOI] [PubMed] [Google Scholar]
  85. Middleton S. J., Shorthouse M., Hunter J. O. Increased nitric oxide synthesis in ulcerative colitis. Lancet. 1993 Feb 20;341(8843):465–466. doi: 10.1016/0140-6736(93)90211-x. [DOI] [PubMed] [Google Scholar]
  86. Moreira A. L., Sampaio E. P., Zmuidzinas A., Frindt P., Smith K. A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993 Jun 1;177(6):1675–1680. doi: 10.1084/jem.177.6.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Morteau O. COX-2: promoting tolerance. Nat Med. 1999 Aug;5(8):867–868. doi: 10.1038/11301. [DOI] [PubMed] [Google Scholar]
  88. Mourelle M., Casellas F., Guarner F., Salas A., Riveros-Moreno V., Moncada S., Malagelada J. R. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology. 1995 Nov;109(5):1497–1502. doi: 10.1016/0016-5085(95)90636-3. [DOI] [PubMed] [Google Scholar]
  89. Muller G. W., Shire M. G., Wong L. M., Corral L. G., Patterson R. T., Chen Y., Stirling D. I. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669–2674. doi: 10.1016/s0960-894x(98)00475-2. [DOI] [PubMed] [Google Scholar]
  90. Murakami-Mori K., Mori S., Nakamura S. p38MAP kinase is a negative regulator for ERK1/2-mediated growth of AIDS-associated Kaposi's sarcoma cells. Biochem Biophys Res Commun. 1999 Nov 2;264(3):676–682. doi: 10.1006/bbrc.1999.1574. [DOI] [PubMed] [Google Scholar]
  91. Murano M., Maemura K., Hirata I., Toshina K., Nishikawa T., Hamamoto N., Sasaki S., Saitoh O., Katsu K. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 2000 Apr;120(1):51–58. doi: 10.1046/j.1365-2249.2000.01183.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Murthy S., Cooper H. S., Yoshitake H., Meyer C., Meyer C. J., Murthy N. S. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther. 1999 Feb;13(2):251–260. doi: 10.1046/j.1365-2036.1999.00457.x. [DOI] [PubMed] [Google Scholar]
  93. Nakamura H., Tsukada H., Oya M., Onomura M., Saito T., Fukuda K., Kodama M., Taniguchi T., Tominaga M., Hosokawa M. Aminoguanidine has both an anti-inflammatory effect on experimental colitis and a proliferative effect on colonic mucosal cells. Scand J Gastroenterol. 1999 Nov;34(11):1117–1122. doi: 10.1080/003655299750024922. [DOI] [PubMed] [Google Scholar]
  94. Neish A. S., Gewirtz A. T., Zeng H., Young A. N., Hobert M. E., Karmali V., Rao A. S., Madara J. L. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science. 2000 Sep 1;289(5484):1560–1563. doi: 10.1126/science.289.5484.1560. [DOI] [PubMed] [Google Scholar]
  95. Neuner P., Klosner G., Schauer E., Pourmojib M., Macheiner W., Grünwald C., Knobler R., Schwarz A., Luger T. A., Schwarz T. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994 Oct;83(2):262–267. [PMC free article] [PubMed] [Google Scholar]
  96. Neurath M. F., Pettersson S., Meyer zum Büschenfelde K. H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996 Sep;2(9):998–1004. doi: 10.1038/nm0996-998. [DOI] [PubMed] [Google Scholar]
  97. Newberry R. D., McDonough J. S., Stenson W. F., Lorenz R. G. Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response. J Immunol. 2001 Apr 1;166(7):4465–4472. doi: 10.4049/jimmunol.166.7.4465. [DOI] [PubMed] [Google Scholar]
  98. Newberry R. D., Stenson W. F., Lorenz R. G. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med. 1999 Aug;5(8):900–906. doi: 10.1038/11341. [DOI] [PubMed] [Google Scholar]
  99. Pan M. H., Lin-Shiau S. Y., Lin J. K. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol. 2000 Dec 1;60(11):1665–1676. doi: 10.1016/s0006-2952(00)00489-5. [DOI] [PubMed] [Google Scholar]
  100. Pender S. L., Breese E. J., Günther U., Howie D., Wathen N. C., Schuppan D., MacDonald T. T. Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology. 1998 Sep;115(3):573–583. doi: 10.1016/s0016-5085(98)70136-2. [DOI] [PubMed] [Google Scholar]
  101. Pender S. L., McKenzie C., Shaida A., MacDonald T. T. Regulation of matrix metalloproteinases in human intestinal mucosa. Ann N Y Acad Sci. 1999 Jun 30;878:581–582. doi: 10.1111/j.1749-6632.1999.tb07733.x. [DOI] [PubMed] [Google Scholar]
  102. Peterson T. C., Davey K. Effect of acute pentoxifylline treatment in an experimental model of colitis. Aliment Pharmacol Ther. 1997 Jun;11(3):575–580. doi: 10.1046/j.1365-2036.1997.00188.x. [DOI] [PubMed] [Google Scholar]
  103. Postema P. T., den Haan P., van Hagen P. M., van Blankenstein M. Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol. 1996 Sep;8(9):929–931. [PubMed] [Google Scholar]
  104. Rachmilewitz D., Karmeli F., Okon E., Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut. 1995 Aug;37(2):247–255. doi: 10.1136/gut.37.2.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Rachmilewitz D., Stamler J. S., Bachwich D., Karmeli F., Ackerman Z., Podolsky D. K. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut. 1995 May;36(5):718–723. doi: 10.1136/gut.36.5.718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Rachmilewitz D., Stamler J. S., Karmeli F., Mullins M. E., Singel D. J., Loscalzo J., Xavier R. J., Podolsky D. K. Peroxynitrite-induced rat colitis--a new model of colonic inflammation. Gastroenterology. 1993 Dec;105(6):1681–1688. doi: 10.1016/0016-5085(93)91063-n. [DOI] [PubMed] [Google Scholar]
  107. Reimund J. M., Dumont S., Muller C. D., Kenney J. S., Kedinger M., Baumann R., Poindron P., Duclos B. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut. 1997 Apr;40(4):475–480. doi: 10.1136/gut.40.4.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Reuter B. K., Wallace J. L. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release. Am J Physiol. 1999 Oct;277(4 Pt 1):G847–G854. doi: 10.1152/ajpgi.1999.277.4.G847. [DOI] [PubMed] [Google Scholar]
  109. Ribbons K. A., Currie M. G., Connor J. R., Manning P. T., Allen P. C., Didier P., Ratterree M. S., Clark D. A., Miller M. J. The effect of inhibitors of inducible nitric oxide synthase on chronic colitis in the rhesus monkey. J Pharmacol Exp Ther. 1997 Feb;280(2):1008–1015. [PubMed] [Google Scholar]
  110. Rincón M., Flavell R. A., Davis R. A. The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radic Biol Med. 2000 May 1;28(9):1328–1337. doi: 10.1016/s0891-5849(00)00219-7. [DOI] [PubMed] [Google Scholar]
  111. Roberts P. J., Riley G. P., Morgan K., Miller R., Hunter J. O., Middleton S. J. The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon. J Clin Pathol. 2001 Apr;54(4):293–297. doi: 10.1136/jcp.54.4.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Knuechel R., Baeuerle P. A., Schölmerich J., Gross V. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998 Aug;115(2):357–369. doi: 10.1016/s0016-5085(98)70202-1. [DOI] [PubMed] [Google Scholar]
  113. Rossignol L., Plantavid M., Chap H., Douste-Blazy L. Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin. Biochem Pharmacol. 1988 Sep 1;37(17):3229–3236. doi: 10.1016/0006-2952(88)90632-6. [DOI] [PubMed] [Google Scholar]
  114. Rowland T. L., McHugh S. M., Deighton J., Ewan P. W., Dearman R. J., Kimber I. Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B. Int Immunopharmacol. 2001 Jan;1(1):49–61. doi: 10.1016/s0162-3109(00)00265-4. [DOI] [PubMed] [Google Scholar]
  115. Rowland T. L., McHugh S. M., Deighton J., Ewan P. W., Dearman R. J., Kimber I. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone. Immunol Lett. 1999 Jun 1;68(2-3):325–332. doi: 10.1016/s0165-2478(99)00055-3. [DOI] [PubMed] [Google Scholar]
  116. Rustin M. H., Gilkes J. J., Robinson T. W. Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J Am Acad Dermatol. 1990 Nov;23(5 Pt 1):941–944. doi: 10.1016/s0190-9622(08)80705-0. [DOI] [PubMed] [Google Scholar]
  117. Salzman A. L., Eaves-Pyles T., Linn S. C., Denenberg A. G., Szabó C. Bacterial induction of inducible nitric oxide synthase in cultured human intestinal epithelial cells. Gastroenterology. 1998 Jan;114(1):93–102. doi: 10.1016/s0016-5085(98)70637-7. [DOI] [PubMed] [Google Scholar]
  118. Sampaio E. P., Sarno E. N., Galilly R., Cohn Z. A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991 Mar 1;173(3):699–703. doi: 10.1084/jem.173.3.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Scheid M. P., Foltz I. N., Young P. R., Schrader J. W., Duronio V. Ceramide and cyclic adenosine monophosphate (cAMP) induce cAMP response element binding protein phosphorylation via distinct signaling pathways while having opposite effects on myeloid cell survival. Blood. 1999 Jan 1;93(1):217–225. [PubMed] [Google Scholar]
  120. Schlöndorff J., Becherer J. D., Blobel C. P. Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J. 2000 Apr 1;347(Pt 1):131–138. [PMC free article] [PubMed] [Google Scholar]
  121. Schreiber S., Nikolaus S., Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 1998 Apr;42(4):477–484. doi: 10.1136/gut.42.4.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Schulze-Osthoff K., Ferrari D., Riehemann K., Wesselborg S. Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology. 1997 Dec;198(1-3):35–49. doi: 10.1016/s0171-2985(97)80025-3. [DOI] [PubMed] [Google Scholar]
  123. Segain J. P., Raingeard de la Blétière D., Bourreille A., Leray V., Gervois N., Rosales C., Ferrier L., Bonnet C., Blottière H. M., Galmiche J. P. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000 Sep;47(3):397–403. doi: 10.1136/gut.47.3.397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Sheskin J., Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis. 1969 Apr-Jun;37(2):135–146. [PubMed] [Google Scholar]
  125. Sheskin J. Further observation with thalidomide in lepra reactions. Lepr Rev. 1965 Oct;36(4):183–187. doi: 10.5935/0305-7518.19650036. [DOI] [PubMed] [Google Scholar]
  126. Sykes A. P., Bhogal R., Brampton C., Chander C., Whelan C., Parsons M. E., Bird J. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther. 1999 Nov;13(11):1535–1542. doi: 10.1046/j.1365-2036.1999.00633.x. [DOI] [PubMed] [Google Scholar]
  127. Vanden Bossche H., Willemsens G., Bellens D., Janssen P. A. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem Pharmacol. 1992 Feb 18;43(4):739–744. doi: 10.1016/0006-2952(92)90238-e. [DOI] [PubMed] [Google Scholar]
  128. Vasiliauskas E. A., Kam L. Y., Abreu-Martin M. T., Hassard P. V., Papadakis K. A., Yang H., Zeldis J. B., Targan S. R. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999 Dec;117(6):1278–1287. doi: 10.1016/s0016-5085(99)70277-5. [DOI] [PubMed] [Google Scholar]
  129. Wallace J. L. Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol. 1988 Apr;66(4):422–425. doi: 10.1139/y88-071. [DOI] [PubMed] [Google Scholar]
  130. Wallace J. L., Vergnolle N., Muscará M. N., Asfaha S., Chapman K., McKnight W., Del Soldato P., Morelli A., Fiorucci S. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology. 1999 Sep;117(3):557–566. doi: 10.1016/s0016-5085(99)70448-8. [DOI] [PubMed] [Google Scholar]
  131. Wang X., Rao J., Studzinski G. P. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Exp Cell Res. 2000 Aug 1;258(2):425–437. doi: 10.1006/excr.2000.4939. [DOI] [PubMed] [Google Scholar]
  132. Williams L. M., Gibbons D. L., Gearing A., Maini R. N., Feldmann M., Brennan F. M. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest. 1996 Jun 15;97(12):2833–2841. doi: 10.1172/JCI118739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Wolffenbuttel B. H., Sels J. P., Huijberts M. S. Rosiglitazone. Expert Opin Pharmacother. 2001 Mar;2(3):467–478. doi: 10.1517/14656566.2.3.467. [DOI] [PubMed] [Google Scholar]
  134. Zingarelli B., Squadrito F., Graziani P., Camerini R., Caputi A. P. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions. 1993 Jul;39(3-4):150–156. doi: 10.1007/BF01998968. [DOI] [PubMed] [Google Scholar]
  135. van Leenen D., van der Poll T., Levi M., ten Cate H., van Deventer S. J., Hack C. E., Aarden L. A., ten Cate J. W. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol. 1993 Aug 15;151(4):2318–2325. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES